XOMA Revenue Jumps 39% in Fiscal Q2
XOMA ( NASDAQ:XOMA ) , a biotechnology royalty aggregator, reported second quarter results on August 13, 2025, for the period ending June 30. The company's revenue ( GAAP ) reached $13.1 million for Q2 2025, surpassing analyst GAAP estimates of $9.39 million.
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
Business development: Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty's recently announced acquisition of LAVA Therapeutics.
Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Day One Biopharmaceutical ( NASDAQ:DAWN ) , Digital Turbine ( NASDAQ:APPS )
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Wednesday. Shares of Super Micro Computer, Inc. SMCI fell sharply in pre-market trading after the company reported worse-than-expected fourth-quarter financial results and cut its FY26 sales guidance.
Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket - Astera Labs ( NASDAQ:ALAB ) , Digital Turbine ( NASDAQ:APPS )
Shares of Astera Labs, Inc. ALAB rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and issued third-quarter guidance above estimates. The company reported a 20% quarter-over-quarter increase in revenue, reaching a record $191.9 ...
Day One ( DAWN ) Q2 Revenue Jumps 313%
Day One Biopharmaceuticals ( NASDAQ:DAWN ) , a clinical-stage biopharmaceutical company focused on developing therapies for pediatric cancers and rare tumor types, reported its earnings for Q2 2025 on August 5, 2025. The main headline: robust growth in OJEMDA ( tovorafenib ) prescription numbers ...
Wall Street Analysts Believe Day One Biopharmaceuticals ( DAWN ) Could Rally 303.46%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 303.5% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in ...
Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025
BRISBANE, Calif., July 22, 2025 ( GLOBE NEWSWIRE ) -- Day One Biopharmaceuticals ( Nasdaq: DAWN ) ( "Day One" or the "Company" ) , a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it ...
Day One Biopharmaceuticals, Inc. ( DAWN ) Reports Q1 Loss, Tops Revenue Estimates
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of 23.91% and 4.90%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Siren Biotechnology Expands Clinical and Scientific Advisory Board with Key Industry Leaders
SAN FRANCISCO, March 05, 2025 ( GLOBE NEWSWIRE ) -- Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, today announced the appointment of three distinguished industry and academic experts to its Clinical and Scientific Advisory Board.
Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations
Jazz reports better-than-expected fourth-quarter results. Its newly issued EPS guidance of $22.50-$24.00 for full-year 2025 surpasses our expectations.
Day One Biopharmaceuticals, Inc. ( DAWN ) Reports Q4 Loss, Tops Revenue Estimates
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of -97.14% and 7.74%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Perrigo Gears Up to Report Q4 Earnings: Here's What to Expect
PRGO's fourth-quarter top line is likely to have benefited from higher net price realization for its products through strategic price increases.
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates
INSM posts wider-than-expected Q4 loss. It reiterates its 2025 sales outlook for Arikayce in the range of $405-$425 million.
BioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 View
BMRN reports better-than-expected fourth-quarter results, driven by encouraging uptake for Voxzogo. It reiterates its guidance of generating $4 billion in total sales by 2027.
Does Day One Biopharmaceuticals ( DAWN ) Have the Potential to Rally 193.16% as Wall Street Analysts Expect?
The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 193.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
New Strong Buy Stocks for February 13th
SYF, SSB, VCYT, DAWN and FISI have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2025.
The Pediatric Brain Tumor Foundation welcomes Day One Biopharmaceuticals' renowned Dr. Samuel C. Blackman to its Board of Directors
BOSTON, Jan. 30, 2025 ( GLOBE NEWSWIRE ) -- The Pediatric Brain Tumor Foundation ( PBTF ) is proud to welcome Dr. Samuel Blackman, MD, PhD to the PBTF's Board of Directors.
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025
Here we present three biotech stocks, ALLO, DAWN and IMCR, which took a beating in 2024 but have upside potential for 2025.
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Day One Biopharmaceutical ( NASDAQ:DAWN )
BRISBANE, Calif., Dec. 17, 2024 ( GLOBE NEWSWIRE ) -- Day One Biopharmaceuticals DAWN ( "Day One" or the "Company" ) , a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy ...
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 17, 2024 ( GLOBE NEWSWIRE ) -- Day One Biopharmaceuticals ( Nasdaq: DAWN ) ( "Day One" or the "Company" ) , a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced ...
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
Dr. Blackman's departure planned for end of ...
Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals ( DAWN ) : Can the Stock Really Move This High?
The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 136.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Carvana ( NYSE:CVNA )
Shares of Carvana Co. CVNA rose in today's pre-market trading after the company reported better-than-expected third-quarter financial results. Carvana reported third-quarter revenue of $3.66 billion, beating the consensus estimate of $3.45 billion, according to Benzinga Pro.
Day One Biopharmaceuticals, Inc. ( DAWN ) Surpasses Q3 Earnings and Revenue Estimates
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of 290% and 144.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
Achieved $20.1 million in OJEMDATM ( tovorafenib ) net product revenue ...
Wall Street Analysts Think Day One Biopharmaceuticals ( DAWN ) Could Surge 140.71%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 140.7% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in ...
Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma ( PTCL ) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val's substantial antitumor activity and generally well-tolerated safety profile -
Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma ( PTCL ) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val's substantial antitumor activity and generally well-tolerated safety profile ...
Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of Directors
SAN DIEGO, Aug. 08, 2024 ( GLOBE NEWSWIRE ) -- Engrail Therapeutics, a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced the appointment of Paul Cayer as chief financial officer, and Saira Ramasastry to the ...
Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday - Meta Platforms ( NASDAQ:META )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Morgan Stanley raised the price target for Zeta Global Holdings Corp. ZETA from $18 to $30.
Day One Biopharmaceuticals, Inc. ( DAWN ) Reports Q2 Loss, Tops Revenue Estimates
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of 92.54% and 810.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Indivior ( NASDAQ:INDV )
Shares of Indivior PLC INDV rose sharply in today's pre-market trading after the company posted better-than-expected second-quarter results and announced an accelerated $100 million share repurchase program. Indivior reported quarterly earnings of 44 cents per share which beat the analyst ...
Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance
PARIS, FRANCE, 25 July 2024 - Ipsen ( Euronext: IPN. ADR: IPSEY ) , a global specialty-care biopharmaceutical company, today presents its financial results for the first half of 2024.
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor
PARIS, FRANCE, and BRISBANE, CALIFORNIA U.S., 25 July 2024 - Ipsen ( Euronext: IPN. ADR: IPSEY ) and Day One Biopharmaceuticals ( Nasdaq: DAWN ) ( Day One ) , announced today a new global partnership outside the U.S. for tovorafenib, an oral, once-weekly, type II RAF inhibitor for pediatric low ...
Xoma ( XOMA ) Surges 6.4%: Is This an Indication of Further Gains?
Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
3 Reasons Why You Should Hold McKesson ( MCK ) Stock for Now
McKesson's (MCK) robust Biologics business raises optimism about the stock.
McKesson ( MCK ) Reaches 52-Week High: What's Aiding the Stock?
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Xoma ( XOMA ) Soars 15.6%: Is Further Upside Left in the Stock?
Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
McKesson Introduces FDA-Approved Prostate Cancer Drug - Boston Scientific ( NYSE:BSX ) , DaVita ( NYSE:DVA )
McKesson Corporation's MCK Biologics by McKesson, its independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Accord BioPharma, Inc. as an exclusive specialty pharmacy provider for CAMCEVI ( leuprolide ) 42mg injection emulsion for subcutaneous use.
McKesson ( MCK ) Introduces FDA-Approved Prostate Cancer Drug
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients improved treatment options for prostate cancer.
Day One ( DAWN ) In-Licenses MabCare Cancer Candidate, Stock Up
Day One (DAWN) gains 11% on in-licensing exclusive worldwide rights to MabCare???s MTX-13, which is set to begin clinical studies for adult and pediatric solid tumor indications.
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate ( ADC ) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
Day One receives exclusive license for development and commercialization of MTX-13 ( DAY301 ) , which received IND clearance by the FDA in April ...
TScan Therapeutics Announces Updates to its Board of Directors
Garry A. Nicholson, an experienced executive with regulatory and commercial expertise, joins the Board of Directors ...
TScan Therapeutics Announces Updates to its Board of Directors - TScan Therapeutics ( NASDAQ:TCRX )
Garry A. Nicholson, an experienced executive with regulatory and commercial expertise, joins the Board of Directors Timothy Barberich retires as Chair; Stephen Biggar, M.D., Ph.D. assumes the role of Chair WALTHAM, Mass., June 14, 2024 ( GLOBE NEWSWIRE ) -- TScan Therapeutics, Inc.
McKesson ( MCK ) Gains 26% YTD: What's Driving the Rally?
McKesson's (MCK) shares have risen year to date on the back of strong fundamentals. Rising volumes of prescription and specialty drugs boost the top line.
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher
EMERYVILLE, Calif., June 12, 2024 ( GLOBE NEWSWIRE ) -- XOMA Corporation ( NASDAQ: XOMA ) , the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta Therapeutics, Inc., related to Day One Biopharmaceuticals' recent sale of its Priority Review ...
Here's Why You Should Hold McKesson ( MCK ) in Your Portfolio Now
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Day One Announces Sale of Priority Review Voucher for $108 Million
BRISBANE, Calif., May 30, 2024 ( GLOBE NEWSWIRE ) -- Day One Biopharmaceuticals ( Nasdaq: DAWN ) ( "Day One" or the "Company" ) , a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, ...
McKesson ( MCK ) Hits 52-Week High: What's Driving the Stock?
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
BrightSpring Health Services Announces Onco360® Was Selected as National Pharmacy Partner for OJEMDA™
LOUISVILLE, Ky., May 20, 2024 ( GLOBE NEWSWIRE ) -- BrightSpring Health Services ( "BrightSpring" or "BrightSpring Health Services" ) ( NASDAQ: BTSG ) is proud that its company, Onco360®, one of the nation's largest independent oncology pharmacies, is being selected as a pharmacy partner by Day ...
